An ideal drug candidate should possess good pharmacological activity, absorption, distribution, metabolism, excretion and toxicity properties. Historically, there are around 6,000 drugs being used in humans and approximately 3,000 still in clinical use, not including herbal medicines. This Pharmaceutical Index series focuses on the profiles of 500 pharmaceutically marketed products from the past two decades. Professor Dr. K. Barry Sharpless is Honorary Editor-in-Chief of this first Index by Pharmacodia. The volume includes 24 NCEs worldwide approved drugs in 2013. Pharmacodia plan to publish two further volumes which will feature 2014 NCEs (32 drugs) and 2015 NCEs (25 drugs).
Table of Contents
Chapter 1: Acotiamide Hydrochloride Hydrate
Chapter 2: Afatinib Dimaleate
Chapter 3: Canagliflozin Hemihydrate
Chapter 4: Cetilistat
Chapter 5: Cobicistat
Chapter 6: Dabrafenib Mesylate.
Chapter 7: Dimethyl Fumarate
Chapter 8: Dolutegravir Sodium
Chapter 9: Efinaconazole
Chapter 10: Elvitegravir
Chapter 11: Glycerol Phenylbutyrate
Chapter 12: Ibrutinib
Chapter 13: Istradefylline
Chapter 14: Levomilnacipran Hydrochloride
Chapter 15: Macitentan
Chapter 16: Olodaterol Hydrochloride
Chapter 17: Ospemifene
Chapter 18: Pomalidomide
Chapter 19: Riociguat
Chapter 20: Simeprevir Sodium
Chapter 21: Sofosbuvir
Chapter 22: Topiroxostat
Chapter 23: Trametinib Dimethyl Sulfoxide
Chapter 24: Vortioxetine Hydrobromide
Appendix I. Abbreviation
Appendix II. Worldwide Approved NCEs (2001-2014)
‘This new series of Pharmaceutical Indexes will be a boon in academia and the pharmaceutical industry, and provide, as well, a significant addition to the therapeutics discovery arsenal. It should also find a wide audience in government, and the business community.’
– K. Barry Sharpless, Nobel Prize Winner in Chemistry, 2001.
‘The most fruitful basis for the discovery of a new drug is to start with an old drug.’
– James W. Black, Nobel Prize Winner in Physiology or Medicine, 1998.